Increasing Helicobacter pylori resistance to antibiotics has ledthat molecular testing is appropriate as a sub to adoption of seven different bismuth quadruple therapies(BQT)in China without differentiation of first-l...Increasing Helicobacter pylori resistance to antibiotics has ledthat molecular testing is appropriate as a sub to adoption of seven different bismuth quadruple therapies(BQT)in China without differentiation of first-line or second-line regimens.The objective of this study was to evaluate the efficacy of susceptibility-guided BQT for patients who had experienced previous treatment failures.A total of 133 patients was included and H.pylori was successfully cultured from 101 patients(75.9%)for subsequent antimicrobial susceptibility testing(AST).Based on the AST results,88 patients completed one of five AST-guided 14-day BQT regimens:esomeprazole and bismuth colloidal pectin,along with either,amoxicillin and clarithromycin(EBAC),amoxicillin and levofloxacin(EBAL),amoxicillin and furazolidone(EBAF),amoxicillin and tetracycline(EBAT),or tetracycline and furazolidone(EBTF).H.pylori eradication rateswere 100%for EBAC(5/5),EBAL(13/13),EBAF(14/14),and EBTF(43/43),but 76.9%for EBAT(10/13).The three patients that failed the EBAT regimenwere all cured after subsequent treatment with the EBTF regimen.Our study demonstrates the excellent efficacy of the AST-guided BQT for referred H.pylori patients,and that the current EBAT regimen,used in clinics,needs to be optimized.In addition,57 of the isolates were subjected to whole-genome sequencing.Analysis of the sequences revealed that point mutations in 23S rRNA correlated well with the phenotypic clarithromycin resistance with a concordance of 91.2%,while the concordance between phenotypic levofloxacin resistance and gyrA point mutations was 82.3%.This suggests that molecular testing is appropriate as a substitute for AST as a more rapid and cost-effective method for determining clarithromycin and levofloxacin resistance in Chinese patients.展开更多
基金This research was funded by the National Natural Science Foundation of China(grant No.81701976)1.3.5 Project for Disciplines of Excellence,West China Hospital,Sichuan University(grant No.ZY2016201).
文摘Increasing Helicobacter pylori resistance to antibiotics has ledthat molecular testing is appropriate as a sub to adoption of seven different bismuth quadruple therapies(BQT)in China without differentiation of first-line or second-line regimens.The objective of this study was to evaluate the efficacy of susceptibility-guided BQT for patients who had experienced previous treatment failures.A total of 133 patients was included and H.pylori was successfully cultured from 101 patients(75.9%)for subsequent antimicrobial susceptibility testing(AST).Based on the AST results,88 patients completed one of five AST-guided 14-day BQT regimens:esomeprazole and bismuth colloidal pectin,along with either,amoxicillin and clarithromycin(EBAC),amoxicillin and levofloxacin(EBAL),amoxicillin and furazolidone(EBAF),amoxicillin and tetracycline(EBAT),or tetracycline and furazolidone(EBTF).H.pylori eradication rateswere 100%for EBAC(5/5),EBAL(13/13),EBAF(14/14),and EBTF(43/43),but 76.9%for EBAT(10/13).The three patients that failed the EBAT regimenwere all cured after subsequent treatment with the EBTF regimen.Our study demonstrates the excellent efficacy of the AST-guided BQT for referred H.pylori patients,and that the current EBAT regimen,used in clinics,needs to be optimized.In addition,57 of the isolates were subjected to whole-genome sequencing.Analysis of the sequences revealed that point mutations in 23S rRNA correlated well with the phenotypic clarithromycin resistance with a concordance of 91.2%,while the concordance between phenotypic levofloxacin resistance and gyrA point mutations was 82.3%.This suggests that molecular testing is appropriate as a substitute for AST as a more rapid and cost-effective method for determining clarithromycin and levofloxacin resistance in Chinese patients.
